Pretargeted Radioimmunotherapy (PRIT™) Using an Antibody-Streptavidin Fusion Protein in Non-Hodgkin's Lymphoma

Pretargeted radioimmunotherapy (PRIT™) decreases the amount of time that radioactivity non-selectively circulates. Our PRIT™ approach is a multi-step method in which a monoclonal antibody is used to target streptavidin to a tumor-associated antigen and biotin is then used to target 90 Y to the strep...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2002-01, Vol.43 (10), p.1971-1973
Main Author: Weiden, Paul L.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antibodies, Neoplasm - therapeutic use
Biotin
Female
Humans
Immunoconjugates - administration & dosage
Immunoconjugates - pharmacokinetics
Immunoconjugates - therapeutic use
Indium Radioisotopes - administration & dosage
Indium Radioisotopes - therapeutic use
Lymphoma, Non-Hodgkin - radiotherapy
Middle Aged
Non-Hodgkin's Lymphoma
Pretargeting
Radioimmunotherapy
Radioimmunotherapy - methods
Recombinant Fusion Proteins - administration & dosage
Recombinant Fusion Proteins - pharmacokinetics
Recombinant Fusion Proteins - therapeutic use
Rhenium - administration & dosage
Rhenium - therapeutic use
Single Chain Fv Streptavidin
Streptavidin
Tissue Distribution
Yttrium Radioisotopes - administration & dosage
Yttrium Radioisotopes - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pretargeted radioimmunotherapy (PRIT™) decreases the amount of time that radioactivity non-selectively circulates. Our PRIT™ approach is a multi-step method in which a monoclonal antibody is used to target streptavidin to a tumor-associated antigen and biotin is then used to target 90 Y to the streptavidin. A genetically engineered antibody streptavidin fusion construct was used to target tumor in a patient with non-Hodgkin's lymphoma. Impressive localization of 90 Y to known and previously unknown areas of adenopathy was observed, thus demonstrating that a genetically engineered fusion protein can selectively target lymphoma cells as part of a clinically meaningful PRIT™ strategy.
ISSN:1042-8194
1029-2403
DOI:10.1080/1042819021000015925